• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
What to do if standard therapy for hepatitis C fails.如果丙型肝炎的标准治疗失败该怎么办。
F1000 Med Rep. 2009 May 28;1:41. doi: 10.3410/M1-41.
2
Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.聚乙二醇化干扰素α-2a和α-2b联合利巴韦林治疗慢性丙型肝炎：系统评价与经济学评估
Health Technol Assess. 2004 Oct;8(39):iii-iv, 1-125. doi: 10.3310/hta8390.
3
Pegylated interferon alfa and ribavirin for children with chronic hepatitis C.聚乙二醇干扰素α和利巴韦林治疗儿童慢性丙型肝炎。
World J Gastroenterol. 2013 Feb 21;19(7):1098-103. doi: 10.3748/wjg.v19.i7.1098.
4
Response to pegylated interferon alpha-2b and ribavirin in children with chronic hepatitis C.聚乙二醇化干扰素α-2b与利巴韦林治疗儿童慢性丙型肝炎的疗效
J Clin Gastroenterol. 2007 Jan;41(1):111-4. doi: 10.1097/MCG.0b013e31802dd2f6.
5
Hydroxychloroquine augments early virological response to pegylated interferon plus ribavirin in genotype-4 chronic hepatitis C patients.羟氯喹增强4型慢性丙型肝炎患者对聚乙二醇化干扰素加利巴韦林的早期病毒学应答。
J Med Virol. 2016 Dec;88(12):2170-2178. doi: 10.1002/jmv.24575. Epub 2016 May 25.
6
Combination therapy with silibinin, pegylated interferon and ribavirin in a patient with hepatitis C virus genotype 3 reinfection after liver transplantation: a case report.水飞蓟宾、聚乙二醇干扰素和利巴韦林联合治疗肝移植后丙型肝炎病毒3型再感染患者：一例报告
J Med Case Rep. 2014 Jul 21;8:257. doi: 10.1186/1752-1947-8-257.
7
Mutations in non-structural 5A and rapid viral response to pegylated interferon-α-2b plus ribavirin therapy are associated with therapeutic efficacy in patients with genotype 1b chronic hepatitis C.非结构 5A 区突变与聚乙二醇干扰素-α-2b 联合利巴韦林治疗快速病毒学应答相关，与基因型 1b 慢性丙型肝炎患者的治疗疗效相关。
Int J Mol Med. 2012 Nov;30(5):1048-52. doi: 10.3892/ijmm.2012.1093. Epub 2012 Aug 9.
8
Chronic hepatitis C genotype 6 responds better to pegylated interferon and ribavirin combination therapy than genotype 1.慢性丙型肝炎 6 型对聚乙二醇干扰素和利巴韦林联合治疗的反应优于 1 型。
J Gastroenterol Hepatol. 2010 Apr;25(4):766-71. doi: 10.1111/j.1440-1746.2009.06163.x.
9
Treatment of chronic hepatitis C in Asia: when East meets West.亚洲慢性丙型肝炎的治疗：当东方与西方相遇时。
J Gastroenterol Hepatol. 2009 Mar;24(3):336-45. doi: 10.1111/j.1440-1746.2009.05789.x.
10
Pegylated interferon-alpha2b plus ribavirin for the treatment of chronic hepatitis C virus genotype 4 infection in patients with normal serum ALT.聚乙二醇干扰素-α2b 联合利巴韦林治疗血清丙氨酸氨基转移酶（ALT）正常的慢性丙型肝炎病毒基因型 4 感染。
Ann Hepatol. 2012 Mar-Apr;11(2):186-93.

本文引用的文献

1
Retreating chronic hepatitis C with daily interferon alfacon-1/ribavirin after nonresponse to pegylated interferon/ribavirin: DIRECT results.聚乙二醇干扰素/利巴韦林治疗无反应后采用每日一次的干扰素 alfacon-1/利巴韦林治疗慢性丙型肝炎：DIRECT 研究结果
Hepatology. 2009 Jun;49(6):1838-46. doi: 10.1002/hep.22871.
2
Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon.低剂量聚乙二醇干扰素对晚期慢性丙型肝炎的长期治疗
N Engl J Med. 2008 Dec 4;359(23):2429-41. doi: 10.1056/NEJMoa0707615.
3
Improved outcomes in patients with hepatitis C with difficult-to-treat characteristics: randomized study of higher doses of peginterferon alpha-2a and ribavirin.具有难治疗特征的丙型肝炎患者的治疗效果改善：高剂量聚乙二醇干扰素α-2a和利巴韦林的随机研究
Hepatology. 2008 Oct;48(4):1033-43. doi: 10.1002/hep.22448.
4
Optimal dose of peginterferon and ribavirin for treatment of chronic hepatitis C.聚乙二醇干扰素和利巴韦林治疗慢性丙型肝炎的最佳剂量
J Viral Hepat. 2008 Sep;15(9):623-33. doi: 10.1111/j.1365-2893.2008.01018.x. Epub 2008 Jul 10.
5
Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: a randomized trial.聚乙二醇干扰素α-2b与基于体重或固定剂量利巴韦林用于慢性丙型肝炎患者：一项随机试验。
Hepatology. 2007 Oct;46(4):971-81. doi: 10.1002/hep.21932.
6
Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha.聚乙二醇干扰素、利巴韦林和α-促红细胞生成素治疗慢性丙型肝炎病毒1型感染
Hepatology. 2007 Aug;46(2):371-9. doi: 10.1002/hep.21712.
7
Peginterferon-alfa2a plus ribavirin for 48 versus 72 weeks in patients with detectable hepatitis C virus RNA at week 4 of treatment.聚乙二醇干扰素α-2a联合利巴韦林治疗48周与72周用于治疗第4周时丙型肝炎病毒RNA可检测的患者。
Gastroenterology. 2006 Aug;131(2):451-60. doi: 10.1053/j.gastro.2006.05.016.
8
Mutations conferring resistance to a hepatitis C virus (HCV) RNA-dependent RNA polymerase inhibitor alone or in combination with an HCV serine protease inhibitor in vitro.单独或与丙型肝炎病毒（HCV）丝氨酸蛋白酶抑制剂联合使用时，赋予对HCV RNA依赖性RNA聚合酶抑制剂耐药性的突变。
Antimicrob Agents Chemother. 2005 Oct;49(10):4305-14. doi: 10.1128/AAC.49.10.4305-4314.2005.
9
Rationale and design of the REPEAT study: a phase III, randomized, clinical trial of peginterferon alfa-2a (40 kDa) plus ribavirin in non-responders to peginterferon alfa-2b (12 kDa) plus ribavirin.REPEAT研究的原理与设计：一项关于聚乙二醇化干扰素α-2a（40 kDa）联合利巴韦林用于聚乙二醇化干扰素α-2b（12 kDa）联合利巴韦林治疗无应答者的III期随机临床试验。
Eur J Gastroenterol Hepatol. 2005 Sep;17(9):899-904. doi: 10.1097/00042737-200509000-00003.
10
Peginterferon alfa-2b and ribavirin for treatment-refractory chronic hepatitis C.聚乙二醇干扰素α-2b与利巴韦林用于治疗难治性慢性丙型肝炎。
J Hepatol. 2005 Aug;43(2):243-9. doi: 10.1016/j.jhep.2005.03.015.

如果丙型肝炎的标准治疗失败该怎么办。

What to do if standard therapy for hepatitis C fails.

作者信息

Tanwar Sudeep, Khakoo Salim

机构信息

Address: Department of Hepatology, Imperial College, St Mary's Campus, South Wharf Road, London W2 1NY, UK.

出版信息

F1000 Med Rep. 2009 May 28;1:41. doi: 10.3410/M1-41.

DOI:10.3410/M1-41
PMID:20052398
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC2801064/
Abstract

The standard of care for treatment of individuals chronically infected with hepatitis C virus is pegylated interferon in combination with ribavirin. Efficacy is closely related to viral genotype. This review outlines potential therapeutic strategies for treatment failures and discusses some of the newer agents currently in development.

摘要

丙型肝炎病毒慢性感染者的标准治疗方案是聚乙二醇化干扰素联合利巴韦林。疗效与病毒基因型密切相关。本综述概述了治疗失败的潜在治疗策略，并讨论了一些目前正在研发的新型药物。